Madrigal Pharmaceuticals
$499.71Change from previous close: −0.84%Absolute change: −$4.25
Company profile
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Headquarters
- 1001 Conshohocken State Road, 19428, West Conshohocken
- Employees
- 915
- Listing
- MDGL · NASDAQ
- Currency
- USD
- Website
- madrigalpharma.com